BiomX Inc. (NYSEMKT:PHGE) Major Shareholder Israel Biofund Gp Limi Orbimed Acquires 348,000 Shares

BiomX Inc. (NYSEMKT:PHGE – Get Rating) major shareholder Israel Biofund Gp Limi Orbimed purchased 348,000 shares of the firm’s stock in a transaction on Monday, February 27th. The shares were purchased at an average cost of $0.24 per share, with a total value of $83,520.00. Following the completion of the transaction, the insider now owns 3,161,489 shares of the company’s stock, valued at approximately $758,757.36. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

BiomX Stock Down 5.5 %

Shares of NYSEMKT PHGE traded down $0.02 during trading hours on Friday, hitting $0.30. 167,060 shares of the stock were exchanged, compared to its average volume of 382,031. The firm’s 50 day simple moving average is $0.35 and its two-hundred day simple moving average is $0.34. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.69 and a current ratio of 5.69. The firm has a market capitalization of $8.99 million, a P/E ratio of -0.27 and a beta of 1.36.

Hedge Funds Weigh In On BiomX

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC raised its position in shares of BiomX by 208.6% in the 4th quarter. Millennium Management LLC now owns 270,848 shares of the company’s stock valued at $51,000 after purchasing an additional 183,091 shares during the last quarter. Jane Street Group LLC acquired a new position in BiomX during the 1st quarter valued at approximately $48,000. Finally, Renaissance Technologies LLC raised its holdings in shares of BiomX by 76.6% in the second quarter. Renaissance Technologies LLC now owns 42,200 shares of the company’s stock worth $31,000 after buying an additional 18,300 shares during the last quarter. 30.55% of the stock is owned by hedge funds and other institutional investors.

BiomX Company Profile

(Get Rating)

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).